Mizuko Mamura

Mizuko Mamura

Auto-generated profile, based on publicly available information

Mizuko Mamura

Department of Molecular Pathology, Tokyo Medical University, Tokyo160-8402, Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2002 in Journal of Experimental Medicine
Verified
Journal Article
Open access
CPCiriaco A. Piccirillo
Ciriaco A. Piccirillo
JLJohn J. Letterio
John J. Letterio
ATAngela M. Thornton
Angela M. Thornton
RMRebecca S. McHugh
Rebecca S. McHugh
MMMizuko Mamura
Mizuko Mamura
Ethan ShevachEthan Shevach
Ethan Shevach
CD4+CD25+ regulatory T cells inhibit organ-specific autoimmune diseases induced by CD4+CD25−T cells and are potent suppressors of T cell activation in vitro. Their mechanism of suppression remains unknown, but most in vitro studies suggest that it is cell contact–dependent and cytokine independent. The role of TGF-β1 in CD4+CD25+ suppressor function remains unclear. While most studies have failed to reverse suppression with anti–transforming growth factor (TGF)-β1 in vitro, one recent study has reported that CD4+CD25+ T cells express cell surface TGF-β1 and that suppression can be completely abrogated by high concentrations of anti–TGF-β suggesting that cell-associated TGF-β1 was the primary effector of CD4+CD25+-mediated suppression. Here, we have reevaluated the role of TGF-β1 in CD4+CD25+-mediated suppression. Neutralization of TGF-β1 with either monoclonal antibody (mAb) or soluble TGF-βRII-Fc did not reverse in vitro suppression mediated by resting or activated CD4+CD25+ T cells. Responder T cells from Smad3−/− or dominant-negative TGF-β type RII transgenic (DNRIITg) mice, that are both unresponsive to TGF-β1–induced growth arrest, were as susceptible to CD4+CD25+-mediated suppression as T cells from wild-type mice. Furthermore, CD4+CD25+ T cells from neonatal TGF-β1−/− mice were as suppressive as CD4+CD25+ from TGF-β1+/+ mice. Collectively, these results demonstrate that CD4+CD25+ suppressor function can occur independently of TGF-β1.

1 December 2003 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MTMasaki Terabe
Masaki Terabe
SMSo Matsui
So Matsui
JPJong-Myun Park
Jong-Myun Park
MMMizuko Mamura
Mizuko Mamura
NNNancy Noben-Trauth
Nancy Noben-Trauth
JBJay A Berzofsky
Jay A Berzofsky
Our previous work demonstrated that cytotoxic T lymphocyte (CTL)-mediated tumor immunosurveillance of the 15-12RM tumor could be suppressed by a CD1d-restricted lymphocyte, most likely a natural killer (NK) T cell, which produces interleukin (IL)-13. Here we present evidence for the effector elements in this suppressive pathway. T cell–reconstituted recombination activating gene (RAG)2 knockout (KO) and RAG2/IL-4 receptor α double KO mice showed that inhibition of immunosurveillance requires IL-13 responsiveness by a non–T non–B cell. Such nonlymphoid splenocytes from tumor-bearing mice produced more transforming growth factor (TGF)-β, a potent inhibitor of CTL, ex vivo than such cells from naive mice, and this TGF-β production was dependent on the presence in vivo of both IL-13 and CD1d-restricted T cells. Ex vivo TGF-β production was also abrogated by depleting either CD11b+ or Gr-1+ cells from the nonlymphoid cells of tumor-bearing mice. Further, blocking TGF-β or depleting Gr-1+ cells in vivo prevented the tumor recurrence, implying that TGF-β made by a CD11b+ Gr-1+ myeloid cell, in an IL-13 and CD1d-restricted T cell–dependent mechanism, is necessary for down-regulation of tumor immunosurveillance. Identification of this stepwise regulation of immunosurveillance, involving CD1-restricted T cells, IL-13, myeloid cells, and TGF-β, explains previous observations on myeloid suppressor cells or TGF-β and provides insights for targeted approaches for cancer immunotherapy, including synergistic blockade of TGF-β and IL-13.

22 June 2006 in Nature
Verified
Journal Article
Closed access
PDF file
BKByung-Gyu Kim
Byung-Gyu Kim
CLCuiling Li
Cuiling Li
WQWenhui Qiao
Wenhui Qiao
MMMizuko Mamura
Mizuko Mamura
BKBarbara Kasperczak
Barbara Kasperczak
JLJohn J. Letterio
John J. Letterio

15 May 2008 in Cancer Research
Verified
Journal Article
Closed access
PDF file
Jeong-Seok NamJeong-Seok Nam
Jeong-Seok Nam
MTMasaki Terabe
Masaki Terabe
MMMizuko Mamura
Mizuko Mamura
MKMi-Jin Kang
Mi-Jin Kang
HCHelen Chae
Helen Chae
LWLalage M. Wakefield
Lalage M. Wakefield
Overexpression of transforming growth factor β (TGF-β) is frequently associated with metastasis and poor prognosis, and TGF-β antagonism has been shown to prevent metastasis in preclinical models with surprisingly little toxicity. Here, we have used the transplantable 4T1 model of metastatic breast cancer to address underlying mechanisms. We showed that efficacy of the anti–TGF-β antibody 1D11 in suppressing metastasis was dependent on a synergistic combination of effects on both the tumor parenchyma and microenvironment. The main outcome was a highly significant enhancement of the CD8+ T-cell–mediated antitumor immune response, but effects on the innate immune response and on angiogenesis also contributed to efficacy. Treatment with 1D11 increased infiltration of natural killer cells and T cells at the metastatic site, and enhanced expression of coactivators (NKG2D) and cytotoxic effectors (perforin and granzyme B) on CD8+ T cells. On the tumor cells, increased expression of an NKG2D ligand (Rae1γ) and of a death receptor (TNFRSF1A) contributed to enhanced immune cell-mediated recognition and lysis. The data suggest that elevated TGF-β expression in the tumor microenvironment modulates a complex web of intercellular interactions that aggregately promote metastasis and progression. TGF-β antibodies reverse this effect, and the absence of a major effect of TGF-β antagonism on any one cell compartment may be critical for a good therapeutic window and the avoidance of autoimmune complications. [Cancer Res 2008;68(10):3835–43]

15 May 2008 in Cancer Research
Verified
Journal Article
Closed access
PDF file
Jeong-Seok NamJeong-Seok Nam
Jeong-Seok Nam
MTMasaki Terabe
Masaki Terabe
MKMi-Jin Kang
Mi-Jin Kang
HCHelen Chae
Helen Chae
NVNga Voong
Nga Voong
LWLalage M. Wakefield
Lalage M. Wakefield
Overexpression of the immunosuppressive cytokine transforming growth factor β (TGF-β) is one strategy that tumors have developed to evade effective immunesurveillance. Using transplantable models of breast and colon cancer, we made the unexpected finding that CD8+ cells in tumor-bearing animals can directly promote tumorigenesis, by a mechanism that is dependent on TGF-β. We showed that CD8+ splenocytes from tumor-bearing mice expressed elevated interleukin (IL)-17 when compared with naive mice, and that CD8+ T cells could be induced to make IL-17 on addition of TGF-β and IL-6 in vitro. Treatment of mice with anti–TGF-β antibodies in vivo reduced IL-17 expression both in the tumor and the locoregional lymph nodes. Although IL-17 has not previously been shown to act as a survival factor for epithelial cells, we found that IL-17 suppressed apoptosis of several tumor cell lines in vitro, suggesting that this altered T-cell polarization has the potential to promote tumorigenesis directly, rather than indirectly through inflammatory sequelae. Consistent with this hypothesis, knockdown of the IL-17 receptor in 4T1 mouse mammary cancer cells enhanced apoptosis and decreased tumor growth in vivo. Thus, in addition to suppressing immune surveillance, tumor-induced TGF-β may actively subvert the CD8+ arm of the immune system into directly promoting tumor growth by an IL-17–dependent mechanism. [Cancer Res 2008;68(10):3915–23]

5 August 2004 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LWLawrence A. Wolfraim
Lawrence A. Wolfraim
TFTania M. Fernandez
Tania M. Fernandez
MMMizuko Mamura
Mizuko Mamura
WFWalter L. Fuller
Walter L. Fuller
RKRajesh Kumar
Rajesh Kumar
JLJohn J. Letterio
John J. Letterio
The receptors for transforming growth factor β (TGF-β) and their signaling intermediates make up an important tumor-suppressor pathway. The role of one of these intermediates — Smad3 — in the pathogenesis of lymphoid neoplasia is unknown.